PRDX1 and cancer: Subgroup analysis based on cancer type suggested that high PRDX1 expression predicted poor OS in patients with OC (HR = 4.60, 95% CI: 2.05-10.34, P < 0.001, fixed effects), OSC (HR = 2.07, 95% CI: 1.43-2.98, P < 0.001, fixed effects), GC (HR = 2.00, 95% CI: 1.44-2.79, P < 0.001, fixed effects), and others (HR = 2.27, 95% CI: 1.72-3.00, P < 0.001, fixed effects).